Evidence map›Paper›PMID 39497078›Full record

ArticleBMC neurology2024

Reliable change indices for the Italian version of the Montreal Cognitive Assessment (MoCA) in non-demented Parkinson's disease patients.

Edoardo Nicolò Aiello, Federica Solca, Silvia Torre, Beatrice Curti, Giulia De Luca, Ruggero Bonetti, Francesco Scheveger, Eleonora Colombo, Alessio Maranzano, Marco Olivero and 16 more

Abstract read
In one paragraph

Article in BMC neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Predictors of cognitive performance in idiopathic adult-onset dystonia.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Edoardo Nicolò AielloDepartment of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, Milano, 20149, MI, Italy.
Federica SolcaDepartment of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, Milano, 20149, MI, Italy.
Silvia TorreDepartment of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, Milano, 20149, MI, Italy.
Beatrice CurtiDepartment of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, Milano, 20149, MI, Italy.
Giulia De LucaDepartment of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, Milano, 20149, MI, Italy.
Ruggero BonettiNeurology Residency Program, Università degli Studi di Milano, Milano, Italy.
Francesco SchevegerNeurology Residency Program, Università degli Studi di Milano, Milano, Italy.
Eleonora ColomboDepartment of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, Milano, 20149, MI, Italy.
Alessio MaranzanoDepartment of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, Milano, 20149, MI, Italy.
Marco OliveroNeurology Residency Program, Università degli Studi di Milano, Milano, Italy.
Claudia MorelliDepartment of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, Milano, 20149, MI, Italy.
Alberto DorettiDepartment of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, Milano, 20149, MI, Italy.
Luca MadernaDepartment of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, Milano, 20149, MI, Italy.
Federico VerdeDepartment of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, Milano, 20149, MI, Italy.
Roberta FerrucciDepartment of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milano, Italy.
Sergio BarbieriFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
Fabiana RuggieroFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
Denise MellaceDepartment of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milano, Italy.
Angelica MarfoliDepartment of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milano, Italy.
Angelica De SandiFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
Alberto Priori"Aldo Ravelli" Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, International Medical School, University of Milan, Milano, Italy.
Gabriella PravettoniDepartment of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milano, Italy.
Vincenzo SilaniDepartment of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, Milano, 20149, MI, Italy.
Nicola TicozziDepartment of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, Milano, 20149, MI, Italy.
Andrea Ciammola *Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, Milano, 20149, MI, Italy.
Barbara Poletti *Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, Milano, 20149, MI, Italy. b.poletti@auxologico.it.ORCID http://orcid.org/0000-0003-4398-2051

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background. The present study aimed at deriving regression-based reliable change indices (RCIs) for the Montreal Cognitive Assessment (MoCA) in an Italian cohort of non-demented Parkinson's disease (PD) patients.

methodsN = 33 consecutive, non-demented PD patients were followed-up at a 5-to-8-month interval (M = 6.6; SD = 0.6) with the MoCA. Practice effects and test-retest reliability were assessed via dependent-sample t-tests and intra-class correlation (ICC) coefficients, respectively. RCIs were derived separately for raw and demographically adjusted MoCA scores according to a standardized regression-based approach by accounting for both baseline confounders (i.e., demographics, disease duration and Unified Parkinson's Disease Rating Scale scores) and retest interval.

resultsNo practice effects were found (t(32) = 0.29; p = .778), with acceptable test-retest reliability being detected (ICC = 0.67). MoCA scores at T0 proved to be the only significant predictor of T1 MoCA performances within both the model addressing raw scores and that addressing adjusted scores (ps < 0.001).

conclusionsThe present study provides Italian practitioners and researchers with regression-based RCIs for the MoCA in non-demented PD patients, which can be reliably adopted for retest interval ≥ 5 and ≤ 8 months without encountering any practice effect.

Indexed as

Mental Status and Dementia TestsParkinson DiseaseAgedCognitive DysfunctionFemaleHumansItalyMaleMiddle AgedReproducibility of ResultsCognitive screeningMontreal Cognitive AssessmentNeuropsychologyParkinson’s diseasePsychometricsReliable change index

Identifiers

PMID39497078
PMCPMC11533291

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.